PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany encouraged by Pfizer COVID-19 vaccine news, cautious on timeline

Mon, 09th Nov 2020 11:28

* Health ministry does not expect first vaccines before Q1
2021

* Spahn says need 55-65% of population to get vaccinated

* German experts set out first guidelines on priority groups
(Adds details from news conference with German health minister)

BERLIN, Nov 9 (Reuters) - Germany's health minister is
encouraged by a Pfizer announcement that its COVID-19
vaccine proved effective in a late-stage trial but still does
not expect a shot to be available before the first quarter of
2021, he said on Monday.

Pfizer and its German partner BioNTech said on
Monday their experimental vaccine was more than 90% effective in
preventing COVID-19 based on initial data from a large study, a
major victory in the fight against the pandemic.

"If this should prove true ... then it would be a good
signal because it shows that this vaccine makes a difference,"
Jens Spahn told a news conference, but added he was cautious on
the timeline because there can always be setbacks.

To break the dynamic of the spread of the coronavirus,
between 55% and 65% of the population will need to be
vaccinated, Spahn said. However, the first vaccines are only
expected to be available in limited amounts.

Germany plans to set up centralised vaccination centres to
inoculate priority groups in the first instance, which will be
supported by mobile teams.

First in line for vaccines should be those who are at risk
due to their age or pre-existing conditions, particularly people
living in nursing homes or long-term care facilities, the German
research centre Leopoldina and the Ethics Council said in a
position paper on priorities for vaccine delivery on Monday.

The second group should include those exposed to the virus
through their jobs, such as front-line healthcare workers, who
could also spread infections to vulnerable people.

For the third group, the experts proposed those who are
needed to maintain public life, including health authority
officials, police and security staff, firefighters and teachers.

Detailed recommendations will only be possible once
late-stage data on the characteristics of vaccines is available,
the experts said.

The German health ministry expects seven potential vaccines
to complete testing this year or next, and is anticipating the
first approvals in the first quarter of 2021, according to a
copy of its national vaccine strategy paper seen by Reuters.

Vaccination will not be mandatory. The German government
will pay for the vaccines, while the cost of setting up
vaccination centres will be borne by the states and public and
private health insurers where appropriate.

To get an overview on the effectiveness of the vaccines,
Germany will collect non-personal data including information on
age, sex, place of residence, vaccination date, vaccine product
and vaccination dose administered, the ministry paper says.
(Reporting by Andreas Rinke and Caroline Copley; Editing by
Maria Sheahan, Michelle Adair and Jan Harvey)

More News
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.